ProCE Banner Activity

CME

An Evening With the Experts: Discussion on the Evolving Immunotherapy Paradigm for NSCLC

Video

In this on-demand webcast from a live symposium, oncology experts Julie Brahmer, MD; Natasha B. Leighl, MD; and Jarushka Naidoo, MB BCH BAO, MHS discuss the latest clinical data informing optimal use of immunotherapy across the spectrum of NSCLC in the context of patient cases.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Faculty

Julie Brahmer

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Natasha Leighl

Natasha Leighl, MD, MMSC, FRCPC, FASCO

Natasha Leighl, MD, FRCPC, FASCO,
Lung Site Lead, Medical Oncology
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Toronto, Canada

Jarushka Naidoo

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Lilly

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC, specifically their relevance in treatment selection in early and advanced disease settings
  • Select optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preference

  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of therapeutic strategies for patients with NSCLC
  • Address factors that can influence response to immune checkpoint inhibitor therapy in individual patients with NSCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Julie Brahmer, MD, MSc, has disclosed that she has received consultant/advisor/speaker fees from Amgen, Blueprint, Bristol-Myers Squibb, Genentech/Roche, Lilly, Janssen, Johnson & Johnson, and Merck, and funds for research support from Bristol-Myers Squibb.

Faculty Disclosure

Primary Author

Natasha Leighl, MD, MMSC, FRCPC, FASCO

Natasha Leighl, MD, FRCPC, FASCO,
Lung Site Lead, Medical Oncology
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Toronto, Canada

Natasha B. Leighl, MD, MMsc, FRCPC, FASCO, has disclosed that she has received funds for research support from Amgen, Array, AstraZeneca, Bayer, Bristol-Myers Squibb, EMD Serono, Guardant Health, Inivata, Lilly, MSD, Novartis, Pfizer, Roche, and Takeda, and consultant/ advisor/speaker fees for Amgen, Bristol-Myers Squibb, GlaxoSmithKline, MSD, Novartis, Puma Biotechnology, Sanofi Genzyme, and Takeda.

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS, has disclosed that she has served on the advisory board for Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, NGM Pharmaceuticals, Pfizer, Roche/Genentech, and Takeda and is on the Data and Safety Monitoring Board for Daiichi Sankyo.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Lisa Kuhns, PhD

Lisa Kuhns, PhD has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 07, 2022, through June 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this program is to improve the knowledge and competence of learners in integrating immunotherapies into treatment plans for patients with NSCLC.